Profit outpacing revenue
Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.
Importance 63 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.
Importance 63 / 95 · growth
EBITDA margin of 23.4% is the widest in 7 years (prior range 7.1% to 21.3%).
Importance 53 / 95 · profitability
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.51×).
Importance 50 / 95 · cash quality
Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.
Peer set used on this page: 3 hospital.
Revenue grew 16.9% a year over 6 years, from ₹702 cr in FY2020 to ₹1,793 cr in FY2026. Net profit fell 12.5% a year over the same period.
Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
Net profit grew 31.5% year on year (FY2025 → FY2026).
Revenue grew 17.3% year on year (FY2025 → FY2026).
Revenue has compounded at 10.7% a year over 7 years (₹4,469 → ₹9,128) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,735 cr (up 17.3% on the same quarter last year) and net profit ₹320 cr (down 2.5%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹2,735 cr, up 17.3% from ₹2,331 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 revenue of ₹2,735 cr is the highest of the 17 quarters on record for this company.
Rule QTR_REVENUE_AT_RECORD
Q2 FY27 EBITDA margin was 23.0%, down 1.80 percentage points from 24.8% a year earlier.
Rule QTR_MARGIN_CHANGED_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 1,928 | +14.8% | 254 | +89.5% | 13.2% |
| Q4 FY25 | 2,007 | +12.4% | 188 | −7.4% | 9.4% |
| Q1 FY26 | 2,167 | +16.6% | 267 | +53.3% | 12.3% |
| Q2 FY26 | 2,331 | +17.3% | 329 | +70.3% | 14.1% |
| Q3 FY26 | 2,265 | +17.5% | 197 | −22.4% | 8.7% |
| Q4 FY26 | 2,365 | +17.8% | 271 | +44.2% | 11.5% |
| Q1 FY27 | 2,545 | +17.5% | 273 | +2.3% | 10.7% |
| Q2 FY27 | 2,735 | +17.3% | 320 | −2.5% | 11.7% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 31.4% in FY2026, against 143% in FY2020. ROE was 2.5% and ROCE 4.0% in FY2026.
EBITDA margin of 23.4% is the widest in 7 years (prior range 7.1% to 21.3%).
Rule MARGIN_AT_MULTI_YEAR_HIGH
ROE improved from 9.1% to 11.0% year on year.
EBITDA margin improved from 21.3% to 23.4% of revenue.
Debt-to-equity was 0.21x in FY2026, against 0.15x in FY2020; interest coverage 2.16x. Operating cash flow was 0.50x net profit.
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.51×).
Rule CFO_CONSISTENTLY_EXCEEDS_PAT
Free cash flow has been positive in 6 of the last 6 years.
Within its 3-company Hospital peer group, it ranks 3 of 3 on return on equity and 2 of 3 on EBITDA margin. Its P/E of 58.7 compares with a peer median of 58.7.
Ranked against 3 hospital (FY2026, consolidated).
FORTIS · 2nd of 3 · set median 17.3%
FORTIS · 2nd of 3 · set median 23.4%
FORTIS · 3rd of 3 · set median 14.3%
FORTIS · 2nd of 3 · set median 58.7×
Trades at 6.13× book — 37% below the hospital median of 9.78×.
Rule PB_BELOW_PEERS
On the trailing twelve months. Last full year: P/E 58.5× · P/S 6.8× · ROE 11.0%.
The share price is down 11.8% over 1 year, up 122% over 3 years (30.4% a year) and up 191% over 5 years (23.9% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 16.7% below its 52-week high.
Over 6 years profit compounded at 50.5% a year while the stock returned 23.9% a year — but FY2020 profit (₹91) was well below the through-cycle level (~₹645), so this rate is inflated by the recovery from a low base.
Rule STOCK_LAGGED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
Nothing is flagged for review for this company.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 702 | 633 | 863 | 1,053 | 1,181 | 1,446 | 1,793 |
| Total income | 1,640 | 825 | 997 | 1,203 | 1,324 | 1,644 | 1,958 |
| EBITDA | 1,006 | 220 | 250 | 283 | 336 | 454 | 562 |
| Profit before tax | 621 | 24 | −9 | 109 | 247 | 114 | 269 |
| Net profit | 513 | 4 | −13 | 96 | 199 | 64 | 230 |
| EPS (₹) | 6.8 | 0.1 | −0.2 | 1.3 | 2.6 | 0.8 | 3.0 |
| Net worth | 8,876 | 8,882 | 8,869 | 8,964 | 9,087 | 9,074 | 9,229 |
| Total debt | 1,303 | 1,349 | 1,193 | 785 | 659 | 2,039 | 1,971 |
| Operating cash flow | — | 32 | 76 | 198 | 242 | 334 | 116 |
| Free cash flow | — | −24 | 50 | 145 | 67 | −31 | −190 |
| Ratio | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Revenue growth YoY | — | -9.8 | 36.3 | 22.1 | 12.2 | 22.4 | 24.0 |
| Profit growth YoY | — | — | — | — | 107.2 | -68.0 | 261.1 |
| Profitability | |||||||
| EBITDA margin % | 143.4 | 34.7 | 28.9 | 26.8 | 28.4 | 31.4 | 31.4 |
| Net margin % | 31.3 | 0.5 | -1.3 | 8.0 | 15.1 | 3.9 | 11.8 |
| Return on equity % | 5.8 | 0.0 | -0.1 | 1.1 | 2.2 | 0.7 | 2.5 |
| Return on capital % | 8.9 | 1.1 | 1.3 | 1.7 | 2.4 | 3.3 | 4.0 |
| Leverage & cash | |||||||
| Debt to equity | 0.15 | 0.15 | 0.13 | 0.09 | 0.07 | 0.22 | 0.21 |
| Cash flow ÷ profit | — | 7.61 | — | 2.06 | 1.21 | 5.24 | 0.50 |
| Current ratio | 0.90 | 0.94 | 1.10 | 0.88 | 1.01 | 0.49 | 0.33 |